Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) generates a steady flow of corporate, product and governance updates that are relevant to investors following EGRX news. As a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, Eagle regularly issues press releases about its commercial portfolio, pipeline programs and capital structure decisions.
Company announcements describe a portfolio that includes PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO, as well as BYFAVO and BARHEMSYS historically commercialized through its wholly owned subsidiary Acacia Pharma Inc. News items have covered transactions such as a royalty purchase agreement to monetize BENDEKA royalties and the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, with Eagle noting that proceeds would support ongoing operations and debt repayment.
Governance and capital markets developments are also a recurring theme in Eagle’s news flow. The company has reported on the adoption and amendment of a limited duration stockholder rights plan, changes to the plan’s purchase price and duration, and cooperation agreements with significant stockholders involving board appointments. In addition, Eagle issues updates on its annual meeting of stockholders, proxy material availability, and the release of audited and unaudited financial statements.
Investors monitoring EGRX news can use this page to follow Eagle’s disclosures on its oncology and critical care products, CNS/metabolic critical care pipeline, financing transactions, and corporate governance actions. Regularly reviewing these updates can help readers understand how Eagle describes the evolution of its product portfolio, pipeline priorities and capital structure over time.
Eagle Pharmaceuticals (EGRX) has announced its intention to file Form 25 with the SEC to complete its delisting from the Nasdaq Global Market. The company's common stock was suspended from Nasdaq trading on October 3, 2024, due to non-compliance with listing requirements, and has been trading on the OTC Expert Market since October 4, 2024. The Form 25 filing, expected on or after November 25, 2024, will finalize the delisting process and deregister the stock under Section 12(b) of the Securities Exchange Act, reducing SEC reporting obligations.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has appointed Christopher Krawtschuk as Chief Financial Officer, effective November 11, 2024. Krawtschuk replaces Steven Ratoff, who steps down as interim CFO but remains on the company's board. Krawtschuk brings extensive pharmaceutical sector experience, having previously served as CFO at bluebird bio and Jubilant Pharma. His background includes roles at Morphosys, where he helped build U.S. commercial operations, and Pfizer, where he provided financial leadership. He began his career at PricewaterhouseCoopers, holds a B.S. in Accounting, and is a licensed CPA.
Eagle Pharmaceuticals has implemented a duration stockholder rights plan in response to significant stock price dislocation and unsolicited third-party accumulation attempts. The plan grants stockholders one preferred share purchase right for each common stock share as of November 11, 2024. These rights become exercisable if any entity acquires or attempts to acquire 10% or more of outstanding common stock (15% for passive institutional investors). When exercisable, each right allows holders to purchase additional shares at $10.00, with a market value of twice the exercise price. The plan expires on October 30, 2025, unless redeemed earlier.
Eagle Pharmaceuticals (Nasdaq: EGRX) received a delisting notification from Nasdaq on August 21, 2024, due to its failure to timely file the Q2 2024 Form 10-Q. This follows a previous notice on August 1, 2024, where Nasdaq granted the company continued listing subject to specific conditions. Eagle must file its 2023 Annual Report by September 30, 2024, and both Q1 and Q2 2024 Form 10-Qs by October 31, 2024. The company plans to file a comprehensive Form 10-K, including restated financial information, and separate Form 10-Q filings to meet these deadlines. However, there's no guarantee that Eagle will meet the compliance dates or maintain its Nasdaq listing.
Eagle Pharmaceuticals received a delisting notification from Nasdaq on May 20, 2024, due to its failure to file key financial forms, including the Q3 2023 Form 10-Q, the 2023 Form 10-K, and the Q1 2024 Form 10-Q. The delisting process will commence if Eagle does not request a hearing by May 28, 2024, which will result in the suspension of their stock trading on May 30, 2024. Eagle plans to request a hearing to potentially extend their compliance period. However, there is no guarantee that such an extension will be granted or that they will regain compliance.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced a Trial in Progress presentation for their ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting in pediatric patients at the SAMBA 2024 Annual Meeting. Preliminary results are expected in the first half of 2025. The study aims to evaluate the potential benefits of amisulpride therapy in pediatric patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.